CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $111,656
- in 2 filings
Net −$111,656. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 47 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-03-14 | Chang David D President and CEO | Shares withheld for taxes | −22,340 | $5.56 | $124K | 2,269,447 |
| 2023-03-14 | SCHMIDT ERIC THOMAS Chief Financial Officer | Shares withheld for taxes | −35,879 | $5.47 | $196K | 304,345 |
| 2023-03-14 | MOORE ALISON Chief Technical Officer | Shares withheld for taxes | −8,351 | $5.51 | $46K | 114,637 |
| 2023-03-14 | Bhavnagri Veer General Counsel | Shares withheld for taxes | −23,628 | $5.67 | $134K | 556,049 |
| 2023-02-13 | Bhavnagri Veer General Counsel | Sale | −3,000 | $6.85 | $21K | 577,677 |
| 2023-01-20 | Roberts Zachary EVP of R&D | Grant or award | +251,908 | 251,908 | ||
| 2023-01-20 | Roberts Zachary EVP of R&D | Grant or award · Stock Option (Right to Buy) | +873,015 | 873,015 | ||
| 2023-01-17 | Bhavnagri Veer General Counsel | Sale | −3,000 | $7.04 | $21K | 580,677 |
| 2022-12-15 | Bhavnagri Veer General Counsel | Sale | −5,602 | $7.53 | $42K | 583,677 |
| 2022-10-07 | Amado Rafael EVP of R&D | Grant or award | +19,120 | 550,410 | ||
| 2022-10-07 | Amado Rafael EVP of R&D | Shares withheld for taxes | −8,464 | $11.83 | $100K | 541,946 |
| 2022-10-03 | Amado Rafael EVP of R&D | Shares withheld for taxes | −8,968 | $11.06 | $99K | 531,290 |
| 2022-08-12 | WITTE OWEN N. Director | Sale | −5,000 | $17.25 | $86K | 218,271 |
| 2022-08-12 | WITTE OWEN N. Director | Sale | −5,000 | $17.25 | $86K | 218,271 |
| 2022-08-11 | WITTE OWEN N. Director | Sale | −10,000 | $16.50 | $165K | 223,271 |
| 2022-08-11 | WITTE OWEN N. Director | Sale | −10,000 | $16.50 | $165K | 223,271 |
| 2022-08-02 | Amado Rafael EVP of R&D and CMO | Sale | −2,000 | $11.97 | $24K | 540,257 |
| 2022-07-08 | Mayo Stephen Director | Grant or award | +35,328 | 35,328 | ||
| 2022-07-08 | Mayo Stephen Director | Grant or award · Stock Option (Right to Buy) | +54,487 | 54,487 | ||
| 2022-07-05 | Amado Rafael EVP of R&D and CMO | Sale | −2,000 | $11.44 | $23K | 542,257 |
Page 8 of 18 · 348 trades